logo BDSP

Base documentaire

  1. Economic implications of lipid-lowering trials : Current considerations in selecting a statin.

    Article - En anglais

    Little doubt remains about the value of lipid-lowering therapy since publication of the results of large, randomized, controlled trials that show decreased total, as well as coronary, mortality with the use of statins for primary and secondary prevention of coronary artery disease, All of the available statins are effective a safe, but they vary greatly in terms of cost-effectiveness.

    Fluvastatin has been determined to be a cost-effective therapeutic agent in the large proportion of the population with mild-to-moderate dyslipidemia who fit treatment guidelines of the National Cholesterol Education Program (NCEP).

    Aforvastatin and simvastatin are cost-effective for the relatively smaller number of patients who require greater reductions in cholesterol.

    Mots-clés Pascal : Cardiopathie coronaire, Traitement, Chimiothérapie, Inhibiteur enzyme, Hydroxymethylglutaryl-CoA reductase, Oxidoreductases, Enzyme, Coût, Economie santé, Efficacité traitement, Critère décision, Dyslipémie, Facteur risque, Forme pharmaceutique, Homme, Prévention, Lipide, Appareil circulatoire pathologie, Hypolipémiant, Métabolisme pathologie

    Mots-clés Pascal anglais : Coronary heart disease, Treatment, Chemotherapy, Enzyme inhibitor, Hydroxymethylglutaryl-CoA reductase, Oxidoreductases, Enzyme, Costs, Health economy, Treatment efficiency, Decision criterion, Dyslipemia, Risk factor, Dosage form, Human, Prevention, Lipids, Cardiovascular disease, Antilipemic agent, Metabolic diseases

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0074237

    Code Inist : 002B02N. Création : 31/05/1999.